Ultra-Low Tidal Volume Mechanical Ventilation in ARDS Through ECMO
- Conditions
- ARDS
- Interventions
- Device: Venovenous ECMO
- Registration Number
- NCT04832789
- Lead Sponsor
- University of Toronto
- Brief Summary
Primary Research Question for the Full ULTIMATE Randomized Clinical Trial (RCT): What is the effect of ultra-protective ventilation facilitated by extracorporeal membrane oxygenation (ECMO) versus best current conventional ventilation (CV) on all-cause hospital mortality among patients with early moderate-severe acute respiratory distress syndrome (ARDS)?
Secondary Research Questions: Among patients with early moderate-severe ARDS, what is the effect of ultra-protective ventilation versus CV on: (1) duration of mechanical ventilation; (2) duration of ICU and hospital stay; (3) organ dysfunction; (4) barotrauma; and (5) mortality at other time-points (ICU discharge, 28-day, 60-day)?
The ULTIMATE Pilot Study: Before embarking on a definitive multinational trial to address the questions listed above, the ULTIMATE Pilot Study has these 3 specific feasibility objectives:
1. To assess adherence to our explicit mechanical ventilation protocols, with particular focus on delivered tidal volumes in both groups;
2. To estimate the rate of patient recruitment and understand barriers to recruitment; and
3. To measure and understand the reasons for crossovers or rescue by ECMO in the control group.
In addition, we will monitor safety issues, recording serious adverse events in both groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 72
-
Age ≥ 18 years
-
Endotracheal mechanical ventilation for ≤ 5 days
-
Early moderate-severe ARDS (Berlin Definition) - all of the following conditions for ≤ 48 hours i. PaO2/FiO2 ≤200 with PEEP > 5 cmH2O ii. bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules iii. respiratory failure not fully explained by cardiac failure or fluid overload iv. within one week of a known insult of new or worsening respiratory symptoms
-
ARDS severity criterion - either 1 of:
- PaO2/FiO2 ≤ 150 mm Hg, on PEEP ≥ 10 cm H2O and FiO2 ≥ 0.5
- Currently receiving any form of ECMO (e.g., venovenous, venoarterial, or hybrid configuration)
- Chronic hypercapnic respiratory failure defined as PaCO2 > 60 mmHg in the outpatient setting
- Home mechanical ventilation (non-invasive ventilation or via tracheotomy), not CPAP
- Actual body weight exceeding 1 kg per centimeter of height
- Severe hypoxemia with PaO2/FiO2 < 80 mmHg
- Expected mechanical ventilation duration < 48 hours
- Treating team is in the process of moving to a palliative mode of care
- Moribund patient not expected to survive 24 hours despite ongoing life-sustaining therapies
- Confirmed diffuse alveolar hemorrhage from vasculitis
- Contraindications to limited anticoagulation (e.g., active GI bleeding, bleeding diathesis)
- Pregnancy - due to unknown effects of PaCO2 changes on placental blood flow
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Ultra-protective ventilation with ECMO Venovenous ECMO -
- Primary Outcome Measures
Name Time Method Number of patients recruited for the study Through study completion, an average of 2 years Patient accrual will be adequate if we recruit 72 patients from 12 sites over 1 year of enrolment
Proportion of patients adhering to the study protocol Through study completion, an average of 2 years Adherence to our explicit ventilation protocols will be adequate if more than 80% of patients have fewer than 10% of monitored values as major protocol violations
Proportion of patients crossing over to VV ECMO Through study completion, an average of 2 years The number of protocol withdrawals or off-protocol treatment with VV ECMO will be acceptable if fewer than 10% of patients crossover or receive VV ECMO, when not allowed by the protocol
- Secondary Outcome Measures
Name Time Method Ventilator-free days Up to 30 days Duration of alive and free of invasive mechanical ventilation
Length of stay Through study completion, an average of 2 years ICU and hospital length of stay in survivors and non-survivors
Number of patients with non-pulmonary organ dysfunction Up to 30 days Using standard definitions
Number of patients with barotrauma Up to 30 days New barotrauma
Mortality Through study completion, an average of 2 years At ICU discharge and 30-days
Health-related quality of life At 6 months post-randomization Health-related quality of life (EQ-5D) via telephone
Trial Locations
- Locations (11)
Mount Sinai Hospital
🇨🇦Toronto, Ontario, Canada
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
University Health Network - Toronto Western Hospital
🇨🇦Toronto, Ontario, Canada
London Health Sciences Centre
🇨🇦London, Ontario, Canada
Unity Health
🇨🇦Toronto, Ontario, Canada
University of Ottawa
🇨🇦Ottawa, Ontario, Canada
New York Presbyterian Hospital
🇺🇸New York, New York, United States
OHSU Hospital
🇺🇸Portland, Oregon, United States
University of Alberta Hospital
🇨🇦Edmonton, Alberta, Canada
University Health Network - Toronto General Hospital
🇨🇦Toronto, Ontario, Canada
Centre Hospitalier Universitaire de Sherbrooke
🇨🇦Sherbrooke, Quebec, Canada